15 October 2021 - The TLV, has developed a web application that will show the regions' use of TNF inhibitors and how much money is theoretically possible to save by using the cheapest product in each substance class.
From 1 October, the regions have not extended the agreements with the pharmaceutical companies for the TNF inhibitors. This means that a refund that has previously accrued to the state and the regions is not paid.